<DOC>
	<DOC>NCT01153997</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of this trial is to investigate the safety profile of recombinant factor XIII (rFXIII) assessed by the occurrence of adverse events in healthy Japanese subjects. In addition pharmacokinetic parameters will be investigated.</brief_summary>
	<brief_title>Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Good general health based on assessment of medical history, physical examination, ECG (electrocardiogram) and clinical laboratory data at screening, as judged by the physician Body mass index (BMI) between 18.027.0 kg/m2 (both inclusive) The receipt of any investigational products for coagulation factor protein within 6 months prior to trial start (screening) Known or suspected allergy to yeast Known bleeding or hematologic disorder Significant history of alcoholism or drug/chemical abuse as judged by the physician or positive result in the alcohol breath test/screen of drugs at the trial start (screening) Smoking more than 10 cigarettes/day or equivalent Not able or willing to refrain from smoking whenever required for the trial procedures Habitual excessive consumption of methylxanthinecontaining beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the physician Excessive consumption of a diet deviating from a normal diet as judged by the physician Strenuous exercise as judged by the physician within 4 days prior to trial start (screening) Surgery or trauma with significant blood loss (500 mL or more blood) within 3 months prior to trial start (screening) Males who are sexually active and not surgically sterilised, who or whose partner are not using adequate contraceptive methods. Adequate contraceptive measures include that the subject uses a condom during intercourse or that the partner practices adequate conception (sterilisation, hormonal intrauterine devices and oral contraceptives).</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>